Release date: 2015-04-03 Beginning in September this year, all babies in the UK will begin receiving vaccinations against Japanese encephalitis. This will make the UK the first country in the world to have a national vaccination program for Japanese encephalitis. Japanese encephalitis caused by Neisseria meningitidis b group accounts for 60% to 80% of all meningitis cases in the UK. On average, there are 1,200 cases of Japanese encephalitis in the UK each year, and one in ten is fatal. Another tenth causes severe injuries such as amputation, deafness, bone deformity and brain damage. Vaccines are available for other less common forms of disease such as c-type meningitis. "The c-type meningitis vaccine has performed quite well. Since its introduction in 1999, the number of cases has been reduced to only a few," said lindaglennie of the British Meningitis Research Foundation. The vaccine, called bexsero, will be available in the UK through a deal between the UK Ministry of Health and the pharmaceutical company gsk, announced last week. A gsk spokesperson said that details will not be disclosed to avoid potential transactions with other countries. Gsk obtained the vaccine from Novartis, a research and development company for bexsero vaccine. At the time, it purchased Novartis's vaccine research and development organization for $5.25 billion. In return, gsk sold its cancer division's assets to Novartis for $16 billion. Two months ago, bexsero was approved in the United States for people between the ages of 10 and 25. Previously, it was used after some outbreaks of meningitis in colleges and universities. For example, in 2013, Princeton University had a meningitis outbreak, and 17,000 students were vaccinated. Source: Chinese Journal of Science Snack Chips,Puffed Food,Healthy Snacks Food,Cheese Flavoured Snacks Montreal Shantou Food Co., Ltd , https://www.montrealsnack.com